Teixobactin: A New Hope in the Development of Novel Antibiotics

Teixobactin

The discovery of teixobactin in January 2015 marks the first time that a new class of antibiotics has been unearthed in nearly 30 years, and its mechanism of action has been hailed as one which may help avoid the issue of antibiotic resistance. The compound is the first member of a novel class of peptidoglycan synthesis inhibitors discovered by NovoBiotic Pharmaceuticals (a spin-off from Northeastern University) during the screening of 10,000 soil organisms using a novel cultivation technique. Teixobactin is produced by the Gram-negative beta-proteobacterium Elephtheria terrae, and has been found to be highly potent in vitro against a broad range of Gram-positive microorganisms including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE). (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

CARs (Chimeric Antigen Receptors): Where Are They Taking Us?

Chimeric Antigen Receptors

There have been some remarkable developments in immune therapy in oncology during the past year. Monoclonal antibody therapy, checkpoint inhibitors and vaccine therapy are rarely out of the scientific and popular media. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Industry-Wide Trends and Challenges – 2014 Wrap-up

Drugs of Today

Regulatory approval and market introduction of new drugs are important indicators of the health and resilience of the biopharmaceutical industry, which after the prolonged recession is making a comeback, as reviewed here recently. Other notable developments and trends offer further insight, providing the context needed for a more accurate assessment of where the industry is now, as well as where it is going. These trends are summarized in a yearly review article published in the journal Drugs of Today, highlights of which are presented here. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Consortium Aims to Fight Ebola with Digital Health Technology

ebola

Ebola may not be making as many headlines as it did several months ago, but the outbreak in West Africa continues to be a problem that needs new solutions. To that end, a consortium led by Scripps Translational Science Institute has been formed to develop a program, using digital health technology, to improve health outcomes for Ebola patients, increase the safety of health care workers and reduce the risk of spreading the virus to others. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

2015 Annual GPhA Meeting: Association Achievements & FDA Progress

GPhA

Over 80% of the prescription drugs dispensed in the US are generic drugs, accounting for only 17% of the dollars spent in the US market. The Generic Pharmaceutical Association (GPhA) annual meeting highlighted the savings and accessibility the generic drug industry has brought to the US healthcare system and patients. In addition to the success, generic companies in the US market are dealing significant challenges, including increased competition, restrictive REMS programs, and labeling rule changes. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Personalized Medicine: The Future of Health Care is Here Today

personalized medicine

Precision medicine has been capturing the headlines big time in the past couple of weeks with major initiatives being created in the U.S. and the UK. Their objective is to marshal resources to be able to accelerate the discovery and delivery of targeted therapies to patients more effectively. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Can Accelerated Drug Approval in Oncology Go Any Faster?

Accelerated Drug Approval

A review article in the New England Journal of Medicine, published in 2012, compared the timelines for novel drugs approved between 2001 and 2010 by the U.S. Food and Drug Administration (FDA), Health Canada and the European Medicines Agency (EMA). For both the U.S. and Europe, 63.7 % of drugs were approved first in the U.S. For those drugs approved in both the U.S. and Canada, 85.7 % were approved first in the U.S. The FDA’s review process was shorter than that of either Health Canada or the EMA. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Biopharma is Roaring at Full Speed into a Precision Medicine Race

Precision Medicine

President Barack Obama didn’t exactly set the biopharma world on fire with the 2015 State of the Union address, devoting only three sentences to drug research and development. What he did say, however – that the federal government will launch “a new precision medicine initiative to bring us closer to curing diseases like cancer and diabetes” – could add momentum to a flurry of dealmaking linking the use of biomarkers and genomic profiling to drug discovery and development. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Pharma Fine Chemicals: Busy, Competitive and a Vital Part of R&D

Informex

The first major tradeshow of the year for the Pharmaceutical Fine Chemicals industry, Informex 2015, took place in New Orleans last week with hundreds of custom manufacturers, product CROs and agent/traders exhibiting and a few thousand people in attendance. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone

Lipids Actually – A Year of Advances in Hyperlipidaemia Therapy

Hyperlipidaemia

End-of-year reviews serve to highlight what is new or what has been headline news during the past year with some predictions or hopes for the coming year. In the case of hyperlipidaemia therapy, 2014 brought three main clinical developments. (more…)

Share on LinkedInTweet about this on TwitterShare on Google+Share on FacebookShare on RedditDigg thisEmail this to someone